RapCo-19 · Project

Rapid Antibody Discovery Platform That Screens Millions of Immune Cells at Once

healthTestedTRL 4

Imagine your immune system has millions of tiny soldiers, each making a slightly different weapon against a virus. Finding the single best weapon among millions is like finding a needle in a haystack. This team built a "Nanoreactor" — essentially a high-speed sorting machine that can test millions of these immune cells from a recovered patient all at once and pick out the absolute best virus-fighting antibodies. They used it on COVID-19 to find antibodies that could be given to sick patients as an instant, temporary shield while vaccines were still being developed.

By the numbers

2,500,000

EUR in EU funding received

millions

single antibody-producing immune cells analysed simultaneously

5-year

research programme behind the Nanoreactor platform

project deliverables completed

The business problem

What needed solving

When a new virus emerges, finding effective antibody treatments takes months or years using traditional methods — too slow for a fast-moving pandemic. Existing screening technologies test immune cells one at a time, creating a bottleneck that delays getting life-saving treatments to critically ill patients. Companies and health agencies need a way to identify the best therapeutic antibodies from recovered patients within weeks, not months.

The solution

What was built

The project built a Nanoreactor-based antibody discovery platform and used it to produce three key outputs: highly purified antibody candidates ready for preclinical studies, proven preclinical safety and efficacy data from rodent models, and recombinant antibody DNA sequences designed for rapid cloning and manufacture by partner facilities.

Audience

Who needs this

Biologics and antibody drug companies seeking faster discovery pipelinesGovernment biodefense agencies building pandemic rapid-response capabilitiesCDMOs wanting licensable antibody candidates with preclinical data packagesVaccine developers needing complementary passive immunisation productsInfectious disease research companies expanding into antibody therapeutics

Business applications

Who can put this to work

Biopharmaceuticals

mid-size

Target: Antibody drug developers and biologics manufacturers

If you are a biologics company struggling with slow antibody discovery timelines — this project developed a Nanoreactor platform that simultaneously screens millions of single antibody-producing immune cells from a single patient sample. Instead of months of traditional screening, this technology rapidly identifies the best virus-neutralising antibodies. The platform was validated through preclinical studies with purified antibody candidates ready for partner manufacturing.

Pandemic Preparedness

enterprise

Target: Government health agencies and biodefense contractors

If you are a public health agency needing rapid-response tools for future outbreaks — this project built a platform designed to go from patient blood sample to therapeutic antibody candidate in weeks rather than months. The system was tested against SARS-CoV-2 with preclinical safety and efficacy data in rodent models. The recombinant antibody DNA sequences are ready to be shared with manufacturing partners for rapid scaling.

Contract Research & Manufacturing

mid-size

Target: CDMOs and contract biologics manufacturers

If you are a contract manufacturer looking to expand your antibody production portfolio — this project generated recombinant antibody DNA sequences specifically designed for cloning and manufacture in partner expression systems. The lead candidates were characterised, expressed, and purified to sufficient quantities for full preclinical studies. This provides a ready-to-license pipeline of antibody candidates with preclinical data packages.

Frequently asked

Quick answers

What does this technology actually cost to license or access?

Pricing details are not disclosed in the project data. The project received EUR 2,500,000 in EU funding through the EIC SME Instrument, which indicates significant investment in the platform. Contact Remedy Biologics Limited directly for licensing terms.

Can this platform scale beyond COVID-19 to other diseases?

The Nanoreactor platform was built over a 5-year research programme as a general-purpose system to rapidly analyse millions of single antibody-producing immune cells. While validated on SARS-CoV-2, the underlying technology is designed to work with any pathogen where convalescent patient samples are available. This makes it applicable to future pandemics and other infectious diseases.

Who owns the IP and how can we license it?

Remedy Biologics Limited, an Irish SME, is the sole consortium partner and likely holds all IP rights. The project specifically produced recombinant antibody DNA sequences designed to be provided to partners for cloning and manufacture. Licensing discussions should be directed to Remedy Biologics.

What regulatory data exists from this project?

The project generated preclinical safety and efficacy data from rodent model studies. This data was shared with the EIC as part of project deliverables. However, no clinical trial data or regulatory submissions are mentioned in the available project information.

How quickly can this platform identify therapeutic antibodies?

The platform is specifically designed for rapid response — the project title itself references speed. The Nanoreactor can simultaneously analyse millions of immune cells from a single patient sample, dramatically compressing the discovery timeline compared to traditional methods. Based on available project data, exact timelines from sample to candidate are not specified numerically.

What stage are the antibody candidates at?

The project delivered highly purified antibody therapy for preclinical studies, proven pre-clinical safety and efficacy in rodent models, and antibody DNA sequences of lead candidates. This represents a preclinical-stage asset with a characterised data package but no clinical validation yet.

Consortium

Who built it

This is a single-company project — Remedy Biologics Limited, an Irish SME, received the full EUR 2,500,000 through the EIC SME Instrument. With no university or research institute partners in the consortium, all IP and know-how sits within one company, which simplifies licensing negotiations. The 100% industry composition and SME status suggest a commercially-minded team focused on getting products to market rather than academic publication. However, the lack of manufacturing or clinical trial partners means scaling will require external partnerships.

How to reach the team

Remedy Biologics Limited (Ireland) — use SciTransfer's coordinator lookup service to find the right contact.

Order a report on this consortium

Next steps

Talk to the team behind this work.

Want an introduction to the Remedy Biologics team? SciTransfer can connect you with the right person and provide a detailed technology brief.

Order a report on this topic More in Health & Biomedical